On January 4, 2021 ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, reported the pricing of an underwritten public offering of 10,310,000 shares of common stock at a price to the public of $4.85 per share, for gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay (Press release, ViewRay, JAN 4, 2021, View Source [SID1234573438]). All of the shares to be sold in the offering will be offered by ViewRay. In addition, ViewRay has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,546,500 shares of common stock at the public offering price, less underwriting discounts and commissions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ViewRay intends to use the net proceeds from the offering for general corporate purposes, including working capital, capital expenditures, continued research and development and commercial expenses.

Piper Sandler & Co. is acting as the sole book-running manager for the offering. B. Riley Securities, Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering.

The offering is expected to close on or about January 7, 2021, subject to satisfaction of customary closing conditions.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission ("SEC") and became effective on February 7, 2019. This offering is being made solely by means of a prospectus supplement and accompanying prospectus included in the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at View Source Alternatively, copies of the final prospectus supplement, when available, and the accompanying prospectus may be obtained by contacting Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN55402, or by telephone at (800) 747-3924, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

On January 4, 2021 Kiromic Biopharma, Inc. (Nasdaq: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and proprietary neural network platform with a therapeutic focus on immuno-oncology, reported the filing of key European patents for its chimeric PD-1 (chPD1) target (Press release, Kiromic, JAN 4, 2021, View Source [SID1234573435]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Kiromic chPD1 receptor targets PD-1 ligands expressed on many different types of cancer cells, including ovarian, pancreatic, prostate, colon, kidney, and breast cancer and melanoma.
Kiromic chPD1-expressing T-cells engage with the PD-1 ligands on the surface of the cancer cells and this interaction activates the T-cells to directly kill the tumor cells.
Kiromic chPD1 has shown in preclinical data to show a cytotoxic response in 9 different in vivo models with 100% long-term PFS with the induction of host memory responses.
chPD1 will be used in the Company’s proprietary chimeric antigen receptor therapy (CAR-T) platform using gamma-delta T-cells (GD-T).
Kiromic’s deep understanding of the tumor micro environment (TME) and the tumors’ escape and masking mechanisms led to development of a promising platform for chimeric antigen receptor therapy (CAR-T).

We believe our allogenic CAR-T platform is significantly stronger with chPD1 target licensed from Longwood University.

Prof. Amorette Barber of Longwood University will be heading up our chPD1 program.

"We believe Prof. Barber’s work will give Kiromic a significant acceleration in the clinical development of its therapy platform and an even more significant advantage over its competitors. We believe this collaboration marks the beginning of an exciting revolution in cell therapies," said Gianluca Rotino, Chief of Strategy and Innovation Officer.

"chPD1 is an exciting and differentiated target for our allogenic CAR-T solid tumors platform. We look forward to updating you in the months ahead as we move closer to filing our first IND with our chPD1 for ovarian cancer," said Maurizio Chiriva-Internati, PhD, CEO of Kiromic Biopharma.

About PD-1 Check-point inhibition

PD-1 has always been a challenge for CAR-T development. PD-1 is the brakes of the immune system, inhibiting immune cells from killing tumor cells.

Traditional PD-1 inhibitors block the PD-1 receptor, "removing the brakes" of T-cell activity. Conversely, Kiromic’s chPD1 not only "removes the brakes" but also engages the PD-1 receptor to "accelerate" T-cell activity.

About Kiromic chPD1 Mechanism of Action

Kiromic’s chPD1 receptor targets PD-1 ligands expressed on many different types of cancer cells, including ovarian, pancreatic, prostate, colon, kidney, and breast cancer and melanoma.

Chimeric PD-1-expressing T-cells engage with the PD-1 ligands on the surface of the cancer cells and this interaction activates the T-cells to directly kill the tumor cells. Chimeric PD-1 T-cells also release cytokines to further initiate immune responses to eradicate the tumor cells.

Through expression of the chPD1 receptor, the inhibitory signal the T-cells would have received through engagement of the PD-1 ligands on tumor cells now acts as an activating signal and induces destruction of tumors. A large variety of cancer types express PD-1 ligands thus the chPD1 T-cells could potentially be used to treat many types of tumors.

On January 4, 2021 Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") reported that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference as follows (Press release, Eagle Pharmaceuticals, JAN 4, 2021, View Source [SID1234573434]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date:

Wednesday, January 13, 2021

Time:

4:30 p.m. Eastern Standard Time

Webcast:

View Source;kiosk=true

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.eagleus.com, under the Investors Section.

On January 4, 2021 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, reported that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the H.C. Wainwright VIRTUAL BioConnect Conference (Press release, Puma Biotechnology, JAN 4, 2021, View Source [SID1234573433]). The presentation will be available on demand beginning at 6:00 a.m. EST on January 11, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The virtual presentation will be available for 30 days on the Company’s website at www.pumabiotechnology.com.

On January 4, 2021 AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, reported that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference at 2:50 p.m. ET on Thursday, January 14, 2021 (Press release, AngioDynamics, JAN 4, 2021, View Source [SID1234573432]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be accessible through the "Investors" section of the Company’s website at www.angiodynamics.com and will be available for replay following the event.